<DOC>
	<DOCNO>NCT00006126</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness peripheral stem cell transplantation treat patient melanoma small cell lung , breast , testicular , kidney cancer metastatic treat surgery .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Treating Patients With Melanoma Small Cell Lung , Breast , Testicular , Kidney Cancer That Metastatic That Can Be Treated With Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity allogeneic peripheral blood stem cell transplantation patient metastatic unresectable small cell lung cancer , breast cancer , testicular germ cell cancer , melanoma , renal cell cancer . II . Determine efficacy regimen patient . OUTLINE : Donors receive filgrastim ( G-CSF ) subcutaneously 4 5 day prior peripheral blood stem cell harvest . Patients assign one three conditioning regimen , depend disease . Group A ( small cell lung cancer ) : Patients receive cyclophosphamide IV 1-2 hour day -7 -6 , etoposide IV 4 hour day -5 , total body irradiation twice daily day -4 -1 . Group B ( breast cancer testicular germ cell cancer ) : Patients receive oral busulfan every 6 hour day -7 -4 total 14 dos . Patients receive cyclophosphamide IV 1-2 hour day -3 -2 . Group C ( renal cell cancer melanoma ) : Patients receive fludarabine IV daily day -8 -4 cyclophosphamide IV day -3 -2 . All group : Patients receive allogeneic peripheral blood stem cell IV 10-20 minute day 0 . Patients follow weekly 3 month , 6 12 month , yearly 5 year . PROJECTED ACCRUAL : A total 19-42 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic unresectable solid tumor one follow type : Small cell lung cancer Extensive stage ( disease outside hemithorax ) relapse Prior cytoreduction platinum/etoposide regimen and/or taxane contain regimen Epithelial breast cancer Stage IV relapse disease Prior cytoreduction adriamycin and/or taxane regimens Testicular germ cell cancer Failure achieve complete remission platinum base chemotherapy Relapsed disease least one salvage regimen Melanoma Metastatic disease fail least one biologic response modifier interleukin2 interferon Relapsed disease involve visceral organ Renal cell cancer Metastatic disease fail least one biologic response modifier interleukin2 interferon Relapsed disease involve visceral organ HLA match one antigen mismatch related donor available Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Under physiologic 60 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL unless due Gilbert 's disease SGOT great 3 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No congestive heart failure LVEF least 40 % Pulmonary : DLCO least 45 % predict OR FEV1/FVC least 50 % predict Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy would preclude study Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>